Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

K is a potential block buster, and if the K-OC trial proves efficacious even though the trial is small, women diagnosed with Stage IV ovarian cancer have a five-year survival rate of only 17% it's off to the races.
With all of this potential the anticipation is at a fever pitch.